soul trial oral semaglutide cardiovascular outcomes 2025 Frontiers soul trial oral semaglutide cardiovascular

2019 Nov 5;322(17):1707-1708

As of June 2023, the FDAs adverse event reporting system (FAERS) has received 76 reported cases of self-harm thoughts, suicidal ideation or attempted suicide related to Ozempic

And when you consider that research into MLM-structured companies shows 99% of participants lose money, according to the FTC, the picture gets more complicated fast

It was noted that setmelanotide would be the first available therapy to target the underlying mechanism of BBS-associated hyperphagia, and that setmelanotide would not be expected to have an impact on manifestations in other body systems (e.g., ocular manifestations)